Article · 20 May 2025
Review articlePublished 19 Feb 2018
Use of bioresorbable scaffolds in cardiology practice today, where do we stand?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Use of bioresorbable technology is long dated in medicine dating back to resorbable sutures to closure devices used after femoral access. Use of bioresorbable scaffolds in interventional cardiology heralded a major breakthrough in terms of its ability to dissolve after a specified period allowing the vessel to reassume its vascular responsiveness (auto-regulation) and patency. Since its introduction in humans in 2006, BVS has shown excellent safety and feasibility at implantation. Initial one year results from major trials and registries shows comparable results to benchmark Drug Eluting Stents Longer term follow up showed higher target vessel revascularization due to higher periprocedural MI and emergence of late scaffold thrombosis risk that is higher than for metallic drug eluting stents. Furthermore vessel autoregulation remained deficient after 2 years in some trials. Abbott decided to halt production as of September 2017 citing low market penetration. Further use in the setting of registries and studies continues. Many of results are yet awaited.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Wael Elabbassi”
- BylineArticles whose byline prints “Robert Hatala & Andaleeb Choudhary”